CA-XSOLLA
17.7.2024 14:01:31 CEST | Business Wire | Press release
Xsolla, a global video game commerce company, announces the launch of Xsolla Instant Game Sales, Instant Launcher, and Instant Cloud Gaming following the release of Instant Web Shop in March 2024.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240717305685/en/
(Graphic: Xsolla)
We have listened to developers express their primary challenges—resource allocation is crucial, yet many struggle to quickly go live with their games and offerings. In response, our streamlined approach facilitates seamless integration and provides developers of any size with instant tools to open new revenue streams for their games. Xsolla partners with game developers and studios of all sizes, offering a swift process to sign license agreements, integrate solutions, and generate revenue promptly, accelerating go-to-market time with direct-to-consumer solutions.
David Stelzer, President of Xsolla, comments: "Xsolla Instant Solutions suite enables developers to quickly and easily launch new monetization channels for their games, attract new paying audiences, and boost revenue by leveraging Xsolla’s comprehensive suite of solutions. We aim to help developers unlock new revenue opportunities while reducing time to market to one day, similar to what we did with the Instant Web Shop launch earlier this year."
Instant Web Shop
Instant Web Shop enables game developers to swiftly set up a fully operational online store for their mobile games, seamlessly transforming a simple link into a revenue-generating platform. This solution increases awareness of the advantages of online purchases and facilitates an effortless shift to a robust LiveOps monetization system, enhancing user engagement and maximizing revenue streams. Instant Web Shop also helps game developers generate more value and purchases with personalization, limited-time offers, promotions, and deep linking.
For more information about Xsolla Instant Web Shop or to sign up, visit: xsolla.pro/ws1
Instant Game Sales
Instant Game Sales empowers developers to create store pages and initiate direct-to-consumer sales by importing content directly from Steam and Epic Game Store. This enables developers to integrate these offerings into their Game Sales page. It facilitates immediate game key sales during pre-orders and pre-launch phases, game releases, and seasonal promotions.
For more information about Xsolla Instant Game Sales or to sign up, visit: xsolla.pro/gs1
Instant Launcher
The Instant Launcher is receiving a significant update to enhance its content delivery system. Developers can import content directly from Steam and Epic Game Store to access a pre-designed launcher app with pre-created design, details, and assets to enable instant direct-to-consumer distribution of their games. Instant Launcher benefits games at any release stage, powering test flights during pre-launch, upcoming launch, and further game monetization. With Launcher, developers can easily directly engage with their audience while cross-promoting their games inside one gaming hub, decreasing the average cost per lead.
For more information about Xsolla Instant Launcher or to sign up, visit: xsolla.pro/launcher1
Instant Xsolla Cloud Gaming
Instant Cloud Gaming offers a self-serve solution for seamless game distribution by rapidly launching a branded cloud gaming platform in as little as 30 minutes to 24 hours. Xsolla Cloud Gaming enables developers to engage directly with their audience by offering pre-launch testing, sharing early versions of their games with the community, and providing the opportunity to demo the game directly from the landing page. Scaling game access to any device ensures quick access to new revenue streams and guarantees reaching more players globally.
For more information about Xsolla Instant Cloud Gaming or to sign up, visit: xsolla.pro/cg1
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in Montreal, London, Berlin, Beijing, Guangzhou, Seoul, Tokyo, Kuala Lumpur, Raleigh, and cities around the world, Xsolla supports major gaming titles like Valve, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.
For additional information and to learn more, please visit: xsolla.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240717305685/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom